ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We first utilize the model to demonstrate the dynamics of CML populations with preexisting BCR-ABL mutations under monotherapy with the standard therapies imatinib, dasatinib and nilotinib.